O	0	5	NOLAN
O	5	6	:
O	7	8	a
O	9	19	randomized
O	19	20	,
O	21	26	phase
O	27	28	2
O	29	34	study
O	35	37	to
O	38	46	estimate
O	47	50	the
O	51	57	effect
O	58	60	of
B-intervention	61	73	prophylactic
I-intervention	74	82	naproxen
I-intervention	83	85	or
I-intervention	86	96	loratadine
O	97	99	vs
B-control	100	102	no
I-control	103	115	prophylactic
I-control	116	125	treatment
O	126	128	on
B-condition	129	133	bone
I-condition	134	138	pain
O	139	141	in
O	142	150	patients
O	151	155	with
O	156	161	early
O	161	162	-
O	162	167	stage
O	168	174	breast
O	175	181	cancer
O	182	191	receiving
O	192	204	chemotherapy
O	205	208	and
O	209	222	pegfilgrastim
O	222	223	.

O	224	228	Mild
O	228	229	-
O	229	231	to
O	231	232	-
O	232	240	moderate
O	241	245	bone
O	246	250	pain
O	251	253	is
O	254	255	a
O	256	264	commonly
O	265	273	reported
O	274	281	adverse
O	282	287	event
O	288	289	(
O	289	291	AE
O	291	292	)
O	293	303	associated
O	304	308	with
O	309	322	pegfilgrastim
O	322	323	.

O	324	326	We
O	327	336	evaluated
O	337	340	the
O	341	347	effect
O	348	350	of
O	351	363	prophylactic
O	364	372	naproxen
O	373	375	or
O	376	386	loratadine
O	387	389	vs
O	390	392	no
O	393	405	prophylactic
O	406	415	treatment
O	416	418	on
O	419	432	pegfilgrastim
O	432	433	-
O	433	443	associated
O	444	448	bone
O	449	453	pain
O	453	454	.

O	455	457	In
O	458	462	this
O	463	467	open
O	467	468	-
O	468	473	label
O	474	479	study
O	480	481	(
O	481	492	NCT01712009
O	492	493	)
O	493	494	,
O	495	500	women
B-age	501	502	≥
I-age	503	505	18
I-age	506	511	years
O	512	514	of
O	515	518	age
B-eligibility	519	523	with
I-eligibility	524	529	newly
I-eligibility	530	539	diagnosed
I-eligibility	540	545	stage
I-eligibility	546	547	I
I-eligibility	547	548	-
I-eligibility	548	551	III
I-eligibility	552	558	breast
I-eligibility	559	565	cancer
I-eligibility	566	569	and
I-eligibility	570	572	an
I-eligibility	573	577	ECOG
I-eligibility	578	589	performance
I-eligibility	590	596	status
I-eligibility	597	598	≤
I-eligibility	599	600	2
I-eligibility	601	604	who
I-eligibility	605	609	were
I-eligibility	610	618	planning
I-eligibility	619	620	≥
I-eligibility	621	622	4
I-eligibility	623	629	cycles
I-eligibility	630	632	of
I-eligibility	633	641	adjuvant
I-eligibility	642	644	or
I-eligibility	645	656	neoadjuvant
I-eligibility	657	669	chemotherapy
I-eligibility	670	674	with
I-eligibility	675	688	pegfilgrastim
I-eligibility	689	696	support
I-eligibility	697	705	starting
I-eligibility	706	708	in
I-eligibility	709	714	cycle
I-eligibility	715	716	1
O	717	721	were
O	722	732	randomized
O	733	734	1
O	734	735	:
O	735	736	1
O	736	737	:
O	737	738	1
O	739	741	to
O	742	749	receive
O	750	758	naproxen
O	758	759	,
O	760	770	loratadine
O	770	771	,
O	772	774	or
O	775	777	no
O	778	787	treatment
O	788	790	to
O	791	798	prevent
O	799	812	pegfilgrastim
O	812	813	-
O	813	823	associated
O	824	828	bone
O	829	833	pain
O	833	834	.

O	835	838	The
O	839	846	primary
O	847	855	endpoint
O	856	859	was
B-outcome-Measure	860	863	all
I-outcome-Measure	863	864	-
I-outcome-Measure	864	869	grade
I-outcome-Measure	870	874	bone
I-outcome-Measure	875	879	pain
I-outcome-Measure	880	882	in
I-outcome-Measure	883	888	cycle
I-outcome-Measure	889	890	1
I-outcome-Measure	891	895	from
I-outcome-Measure	896	898	AE
I-outcome-Measure	899	908	reporting
O	908	909	.

O	910	919	Secondary
O	920	929	endpoints
O	930	938	included
B-outcome-Measure	939	943	bone
I-outcome-Measure	944	948	pain
I-outcome-Measure	949	951	in
I-outcome-Measure	952	958	cycles
I-outcome-Measure	959	960	2
I-outcome-Measure	960	961	-
I-outcome-Measure	961	962	4
I-outcome-Measure	963	966	and
I-outcome-Measure	967	973	across
I-outcome-Measure	974	977	all
I-outcome-Measure	978	984	cycles
I-outcome-Measure	985	989	from
I-outcome-Measure	990	992	AE
I-outcome-Measure	993	1002	reporting
O	1003	1006	and
B-outcome-Measure	1007	1014	patient
I-outcome-Measure	1014	1015	-
I-outcome-Measure	1015	1023	reported
I-outcome-Measure	1024	1028	bone
I-outcome-Measure	1029	1033	pain
I-outcome-Measure	1034	1036	by
I-outcome-Measure	1037	1042	cycle
I-outcome-Measure	1043	1046	and
I-outcome-Measure	1047	1053	across
I-outcome-Measure	1054	1057	all
I-outcome-Measure	1058	1064	cycles
O	1064	1065	.

B-total-participants	1066	1069	Six
I-total-participants	1070	1077	hundred
O	1078	1086	patients
O	1087	1091	were
O	1092	1100	enrolled
O	1100	1101	.

O	1102	1106	Most
O	1107	1115	patients
O	1116	1117	(
O	1117	1119	83
O	1119	1120	.
O	1120	1121	0
O	1121	1122	%
O	1122	1123	)
O	1124	1128	were
B-ethinicity	1129	1134	white
O	1134	1135	,
O	1136	1139	and
O	1140	1144	mean
O	1145	1146	(
O	1146	1148	SD
O	1148	1149	)
O	1150	1153	age
O	1154	1157	was
B-age	1158	1160	54
I-age	1160	1161	.
I-age	1161	1162	2
I-age	1163	1164	(
I-age	1164	1166	11
I-age	1166	1167	.
I-age	1167	1168	1
I-age	1168	1169	)
I-age	1170	1175	years
O	1175	1176	.

O	1177	1180	The
B-outcome	1181	1191	percentage
I-outcome	1192	1194	of
I-outcome	1195	1203	patients
I-outcome	1204	1208	with
I-outcome	1209	1212	all
I-outcome	1212	1213	-
I-outcome	1213	1218	grade
I-outcome	1219	1223	bone
I-outcome	1224	1228	pain
O	1229	1231	in
O	1232	1237	cycle
O	1238	1239	1
O	1240	1244	from
O	1245	1247	AE
O	1248	1257	reporting
O	1258	1260	in
O	1261	1264	the
O	1265	1273	naproxen
O	1273	1274	,
O	1275	1285	loratadine
O	1285	1286	,
O	1287	1290	and
O	1291	1293	no
O	1294	1305	prophylaxis
O	1306	1312	groups
O	1313	1316	was
B-iv-bin-percent	1317	1319	40
I-iv-bin-percent	1319	1320	.
I-iv-bin-percent	1320	1321	3
O	1321	1322	,
B-iv-bin-percent	1323	1325	42
I-iv-bin-percent	1325	1326	.
I-iv-bin-percent	1326	1327	5
O	1327	1328	,
O	1329	1332	and
B-cv-bin-percent	1333	1335	46
I-cv-bin-percent	1335	1336	.
I-cv-bin-percent	1336	1337	6
I-cv-bin-percent	1337	1338	%
O	1338	1339	,
O	1340	1352	respectively
O	1352	1353	;
O	1354	1365	differences
O	1366	1373	between
O	1374	1377	the
O	1378	1387	treatment
O	1388	1394	groups
O	1395	1399	were
O	1400	1403	not
O	1404	1417	statistically
O	1418	1429	significant
O	1429	1430	.

O	1431	1438	Maximum
O	1438	1439	,
O	1440	1444	mean
O	1444	1445	,
O	1446	1449	and
O	1450	1454	area
O	1455	1460	under
O	1461	1464	the
O	1465	1470	curve
O	1471	1474	for
B-outcome	1475	1482	patient
I-outcome	1482	1483	-
I-outcome	1483	1491	reported
I-outcome	1492	1496	bone
I-outcome	1497	1501	pain
O	1502	1506	were
O	1507	1519	consistently
O	1520	1525	lower
O	1526	1528	in
O	1529	1532	the
O	1533	1541	naproxen
O	1542	1545	and
O	1546	1556	loratadine
O	1557	1563	groups
O	1564	1568	than
O	1569	1571	in
O	1572	1575	the
O	1576	1578	no
O	1579	1590	prophylaxis
O	1591	1596	group
O	1596	1597	;
O	1598	1602	some
O	1603	1605	of
O	1606	1611	these
O	1612	1623	differences
O	1624	1628	were
O	1629	1640	significant
O	1640	1641	.

O	1642	1652	Loratadine
O	1653	1656	was
O	1657	1667	associated
O	1668	1672	with
O	1673	1678	fewer
B-outcome	1679	1688	treatment
I-outcome	1688	1689	-
I-outcome	1689	1696	related
I-outcome	1697	1700	AEs
I-outcome	1701	1704	and
I-outcome	1705	1721	discontinuations
O	1722	1726	than
O	1727	1735	naproxen
O	1735	1736	.

O	1737	1742	Given
O	1743	1746	its
O	1747	1759	tolerability
O	1759	1760	,
O	1761	1764	its
O	1765	1769	ease
O	1770	1772	of
O	1773	1787	administration
O	1787	1788	,
O	1789	1792	and
O	1793	1796	its
O	1797	1806	potential
O	1807	1814	benefit
O	1814	1815	,
O	1816	1825	treatment
O	1826	1830	with
O	1831	1841	loratadine
O	1842	1848	should
O	1849	1851	be
O	1852	1862	considered
O	1863	1865	to
O	1866	1870	help
O	1871	1878	prevent
O	1879	1883	bone
O	1884	1888	pain
O	1889	1891	in
O	1892	1900	patients
O	1901	1910	receiving
O	1911	1923	chemotherapy
O	1924	1927	and
O	1928	1941	pegfilgrastim
O	1941	1942	.

O	1943	1957	ClinicalTrials
O	1957	1958	.
O	1958	1961	gov
O	1962	1963	;
O	1964	1975	NCT01712009
O	1975	1976	.
